Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup

Seeking Alpha7minutes ago

Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250

Moomoo News05:33 ET · Ratings

Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?

Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?

wallstreetcn02:50 ET

News Highlights: Top Company News of the Day - Friday at 7 PM ET

Dow Jones19:00 ET

Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com

Barron's17:58 ET

FDA Approves First Medication for Obstructive Sleep Apnea

PR Newswire17:39 ET